AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30908592
Drug: Restrictive oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive oxygen therapy (no supplemental oxygen if SpO2 ≥ 94%, n=21)
Trial: 30908592
Drug: Liberal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal oxygen therapy (intubated patients: FiO2 1.0 in trauma bay, 0.8-1.0 elsewhere; spontaneously breathing patients: 15 L/min via non-rebreather mask, n=20)
Trial: 28394418
Drug: Every‐2‐week dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every‐2‐week dosing regimen of Peginterferon beta‐1a
Trial: 26081864
Drug: Rehab-let (touchscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehab-let (touchscreen tablet self-training protocol)
Trial: 23569345
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg IL‐1Ra via ear vein 18 h, 2 d and 4 d after D‐gal induction (Group B)
Trial: 23569345
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg IL‐1Ra via ear vein 18 h after D‐gal induction, MSCs transplantation at 24 h after D‐gal induction, and 2 mg/kg IL‐1Ra via ear vein 1 d and 3 d after surgery (Group D)
Trial: 23569345
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL saline via portal vein 24 h after D‐gal induction (Group A)
Trial: 23569345
Drug: Approximately 1
RxNorm normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 1 × 10(8) GFP‐MSCs suspended in 40 mL normal saline via portal vein 24 h after D‐gal induction (Group C)
Trial: 22143217
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care education for caregivers (6 weeks duration)
Trial: 22143217
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral care from control group caregivers
Trial: 20795842
Drug: Atenolol therapy
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol therapy
Trial: 11474773
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg sodium rabeprazole
Trial: 9604880
Drug: Nicotinamide (slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (slow release, 1.2 g x m(‐2) x day(‐1))
Trial: 26817206
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplement (2,000 IUs/day)
Trial: 23284036
Drug: Protocolized patient‐tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized patient‐tailored treatment (PPT) of symptoms
Trial: 19084937
Drug: 4-week pegylated
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Trial: 19084937
Drug: 12-week pegylated
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Trial: 18039239
Drug: Intensive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive group physical therapy (PT)
Trial: 14979498
Drug: Ipratropium (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (2 puffs of 20 microg administered four times daily)
Trial: 9652994
Drug: MFP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFP plus calcium (20 mg of equivalent fluoride + 1000 mg calcium)
Trial: 22980891
Drug: L‐FVOO (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐FVOO (250 mg total phenols/kg)
Trial: 22980891
Drug: M‐FVOO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M‐FVOO (500 mg total phenols/kg)
Trial: 22980891
Drug: H‐FVOO (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H‐FVOO (750 mg total phenols/kg)
Trial: 17244785
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg daily (PIO)
Trial: 11965508
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (60 mg RE to mothers and 7.5 mg RE to infants with each OPV dose)
Trial: 9825815
Drug: Increased doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased doses of tacrolimus (median increase of 1.89-fold, range: 1.2-5 mg)
Trial: 2466045
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 micrograms, twice daily, sc)
Trial: 21955635
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered in the same way
Trial: 24196330
Drug: Nd:YAG 1440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd:YAG 1440 nm laser treatment
Trial: 18203019
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 once weekly for 4 weeks
Trial: 18203019
Drug: Rituximab in
RxNorm normalized name: rituximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab in combination with interferon alpha-2a (IFN) (n = 33)
Trial: 11812685
Drug: Full-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose aprotinin regimen
Trial: 10910828
Drug: Half-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose aprotinin regimen
Trial: 8760643
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of lorazepam, orally, one hour before induction of anaesthesia
Trial: 1425205
Drug: Seaprose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaprose (60 mg/8 h) plus erythromycin (500 mg/8 h)
Trial: 1425205
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg/8 h) plus placebo
Trial: 3967167
Drug: Intravenous dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dacarbazine plus intradermal injection of the methanol‐extracted residue of bacillus Calmette‐Guerin (BCG)
Trial: 3967167
Drug: Intravenous dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dacarbazine alone
Trial: 21190639
Drug: Medication switches
RxNorm normalized name: witch hazel Medicated Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication switches
Trial: 15673878
Drug: Small-dose IV
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose IV ketamine (0.5 mg/kg bolus followed by 3 mcg/kg/min during surgery and 1.5 mcg/kg/min for 48 hours)
Trial: 15673878
Drug: Small-dose IV
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-dose IV ketamine
Trial: 8866316
Drug: Demineralized freeze‐dried
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demineralized freeze‐dried bone allograft reconstituted with 50 mg/ml tetracycline (DFDBA + TCN)
Trial: 1333782
Drug: Single, high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, high dose of aspirin
Trial: 6474351
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg and dipyridamole 75 mg
Trial: 24587006
Drug: Subcutaneous palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous palonosetron
Trial: 21769988
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about the association between cognitive problems and chemotherapy
Trial: 21769988
Drug: No information
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No information about the association between cognitive problems and chemotherapy
Trial: 18093331
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavior therapy (8 weekly lessons, support by e-mail)
Trial: 18093331
Drug: Internet-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based problem-solving therapy (5 weekly lessons, support by e-mail)
Trial: 16357163
Drug: GDNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDNF treatment in pancreatic cancer cells with G691S RET polymorphism
Trial: 16357163
Drug: GDNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDNF treatment in pancreatic cancer cells without specific mention of RET polymorphism
Trial: 10919583
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 1-3 mg/kg daily
Trial: 1526096
Drug: i.m. immunoglobulins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. immunoglobulins and oral polyvalent bacterial vaccine
Trial: 1526096
Drug: vaccine only
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaccine only
Trial: 29154271
Drug: Subcutaneous adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adipose tissue biopsies from AD patients
Trial: 29154271
Drug: Subcutaneous adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adipose tissue biopsies from cognitively healthy proxies
Trial: 24041789
Drug: 7.5‐µg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5‐µg dose of A/Vietnam vaccine
Trial: 24041789
Drug: Booster immunization
RxNorm normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster immunization with A/Indonesia(H5N1) vaccine
Trial: 20085866
Drug: Plasma nucleosome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma nucleosome levels before therapy cycles 2 and 3
Trial: 16259492
Drug: Monthly support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly support group or monthly phone call from a nurse (follow-up conditions)
Trial: 12106618
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (88 microg, twice daily for 6 weeks)
Trial: 12106618
Drug: Zafirlukast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast (20 mg, twice daily for 6 weeks)
Trial: 28542868
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml lidocaine 2%
Trial: 28542868
Drug: 15 ml
RxNorm normalized name: ethanol 0.15 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml saline
Trial: 21585062
Drug: Acu-moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acu-moxibustion treatment (12 weeks, once every other day, main acupoints: Feishu, Geshu, Ganshu, Pishu, Shenshu; moxibustion applied for about 3 min each time)
Trial: 21585062
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral Acitretin capsules, 20 mg/d for 12 weeks)
Trial: 19175613
Drug: Non-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific treatment
Trial: 14742356
Drug: Aprotinin regimen
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin regimen with a bolus of 1 x 10(6) kallikrein inhibiting units (KIU) before CPB, 1 x 10(6) KIU in the priming solution, and a continuous infusion of 250,000 KIU/h during CPB.
Trial: 14742356
Drug: Heparin management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin management according to Hepcon HMS Plus.
Trial: 9671343
Drug: Mirtazapine (15-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15-60 mg/day)
Trial: 11476127
Drug: Venlafaxine (75-375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (75-375 mg/day, twice a day)
Trial: 9782221
Drug: Dirithromycin (D)
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin (D) 500 mg once daily for 5 days
Trial: 8156516
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 1 after CY
Trial: 8156516
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (CY) 2400 mg per M2 as a single-day dose and vincristine (VCR) 1.4 mg per M2 given on Day 9 after CY
Trial: 8156516
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard doses of chemotherapy)
Trial: 30762217
Drug: Arthroscopic suprapectoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopic suprapectoral intraosseous implant-free biceps tenodesis (ASIIBT) with Cobra Guide (CG)
Trial: 26625506
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive ($8 per medication per month)
Trial: 26625506
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive ($8 per medication per month) in diabetics
Trial: 26625506
Drug: Financial incentive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial incentive ($8 per medication per month) in nondiabetics
Trial: 10855738
Drug: Trandolapril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2 mg)
Trial: 8855526
Drug: Pulse-spray thrombolysis
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse-spray thrombolysis plus angioplasty
Trial: 27502800
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (75 mg/im)
Trial: 24337978
Drug: QGC001 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGC001 (10, 50, 125, 250, 500, 750, 1,000, and 1,250 mg)
Trial: 22395187
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula supplemented with 2.0 g/L FOS
Trial: 22395187
Drug: Infant formula
RxNorm normalized name: Infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant formula supplemented with 3.0 g/L FOS
Trial: 16036387
Drug: Magnesium (2
RxNorm normalized name: magnesium gluconate 12.5 mg magnesium (250 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (2 g/h)
Trial: 16036387
Drug: Fenoterol (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (270 microg/h) + Verapamil (0.2 mg/h)
Trial: 16036387
Drug: Nifedipine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (0.25 mg/ml) in vitro
Trial: 10550454
Drug: Estradiol 25
RxNorm normalized name: estradiol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 25 mg/day
Trial: 10550454
Drug: Estradiol 50
RxNorm normalized name: estradiol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 50 mg/day
Trial: 10550454
Drug: Estradiol 75
RxNorm normalized name: ESTRADIOL 75MCG/DAY (VIVELLE-DOT) PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol 75 mg/day
Trial: 10550454
Drug: Estradiol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (all doses)
Trial: 8905799
Drug: Erythromycin 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1,200 mg/day for 10 days
Trial: 6140938
Drug: ICI 118551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118551 20 mg
Trial: 6140938
Drug: ICI 118551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118551 50 mg
Trial: 28303364
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (500 mL daily for one week)
Trial: 25209368
Drug: Phosphate binding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate binding medication adherence intervention
Trial: 21844061
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium phosphate (1.6 mg/kg per day for 3 days)
Trial: 12971032
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg as intact tablets with water
Trial: 12971032
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg as tablets crushed in acidic juice
Trial: 12971032
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg as intact tablets
Trial: 8218758
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg each morning)
Trial: 8218758
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg at night time)
Trial: 3578422
Drug: 5000 U
RxNorm normalized name: lipase 5000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 U sodium heparin
Trial: 3578422
Drug: 7500 U
RxNorm normalized name: amylase 97500 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7500 U sodium heparin
Trial: 3578422
Drug: 10000 U
RxNorm normalized name: papain 10000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10000 U sodium heparin
Trial: 3578422
Drug: Heparin neutralization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin neutralization activity
Trial: 29125719
Drug: Obiltoxaximab 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obiltoxaximab 4 mg/kg
Trial: 29125719
Drug: Obiltoxaximab 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obiltoxaximab 8 mg/kg
Trial: 29125719
Drug: Obiltoxaximab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obiltoxaximab 16 mg/kg
Trial: 29125719
Drug: Obiltoxaximab 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obiltoxaximab 20 mg/kg
Trial: 29125719
Drug: Obiltoxaximab 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obiltoxaximab 24 mg/kg
Trial: 29125719
Drug: Obiltoxaximab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obiltoxaximab (all doses)
Trial: 24439682
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavioural treatment
Trial: 24439682
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural treatment
Trial: 24439682
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual improved with Smith's norms
Trial: 23275372
Drug: Grape polyphenols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape polyphenols (PPs) 2 g/day
Trial: 26689304
Drug: Integrative cognitive‐affective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive‐affective therapy for BN (ICAT‐BN)
Trial: 27467700
Drug: Enhanced cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive behavior therapy (CBT‐E)
Trial: 23000708
Drug: Calcium‐incorporated titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐incorporated titanium implants
Trial: 23000708
Drug: Control titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control titanium implants
Trial: 8718563
Drug: Cilazapril (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (1 mg single dose at the end of HD session)
Trial: 1572445
Drug: HDM injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM injections
Trial: 3917653
Drug: Bestatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin (30 mg/day) and FT‐207 (0.6 g/day p.o.) after 1/2MF'C regimen (mitomycin C 2 mg and cytosine arabinoside 20 mg i.v. twice a week for 3 weeks, FT‐207 400 mg/day i.v. for 3 weeks)
Trial: 31566694
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) plus usual obstetric care
Trial: 31566694
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound treatment plus usual obstetric care
Trial: 24273968
Drug: Bushen Yijing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Yijing Decoction (BYD), tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Trial: 24273968
Drug: Bushen Yijing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Yijing Decoction (BYD), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Trial: 24273968
Drug: tamoxifen tablet
RxNorm normalized name: tamoxifen Oral Tablet
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tamoxifen tablet (TT), Licorzine Capsule (LC), and Vitamin E Soft Capsule (VESC)
Trial: 24273968
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group and control group 1